Does increased niacin need reflect pressure on the kynurenine pathway?

Tryptophan catabolism serves as the body's primary de novo pathway for synthesizing nicotinamide adenine dinucleotide (NAD+) and niacin. When dietary niacin is insufficient, the metabolic pressure shifts entirely onto this pathway, carrying significant biochemical consequences.

De novo NAD+ synthesis pathway

• Tryptophan is metabolized via the kynurenine pathway to produce quinolinic acid, which is then converted by quinolinate phosphoribosyltransferase (QPRT) into nicotinic acid mononucleotide (NaMN)—the committed precursor for NAD+ and niacin.
• This pathway operates at a low baseline efficiency under normal conditions; less than 2% to 3% of dietary tryptophan is converted, establishing a standard metabolic ratio where 60 mg to 67 mg of dietary tryptophan yields just 1 mg of niacin equivalent.

Feedback inhibition and pathway pressure

• Systemic NAD+ and nicotinamide exert vital negative feedback control over the kynurenine pathway. When exogenous niacin is depleted, this feedback inhibition is lost.
• Without this regulatory brake, upstream rate-limiting enzymes—tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO)—are upregulated, driving a high volume of tryptophan flux down the pathway.

Downstream bottlenecks and neurotoxicity

• Rapid tryptophan flux frequently overwhelms downstream clearing enzymes like QPRT. Furthermore, co-factor deficiencies, such as a vitamin B6 deficiency, impair kynureninase activity and block normal catabolism.
• These metabolic bottlenecks trigger the accumulation of quinolinic acid, a potent NMDA receptor agonist that induces neuroinflammation, reactive oxygen species (ROS) production, and neuroexcitotoxicity.

Bottom line

• An increased biochemical need for niacin directly reflects metabolic pressure on the kynurenine pathway. Depleted NAD+ levels remove feedback inhibition, forcing tryptophan flux through a pathway prone to bottlenecks, which can drive the accumulation of the neurotoxic intermediate quinolinic acid.